Ann Cotter Net Worth

The estimated Net Worth of Ann Marie Cotter is at least $1.06 Thousand dollars as of 3 May 2021. Ms. Cotter owns over 19,444 units of Zomedica Pharmaceuticals stock worth over $1,059 and over the last 4 years she sold ZOM stock worth over $0. In addition, she makes $0 as Chief Financial Officer and Secretary at Zomedica Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Cotter ZOM stock SEC Form 4 insiders trading

Ann has made over 2 trades of the Zomedica Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 19,444 units of ZOM stock worth $3,111 on 3 May 2021.

The largest trade she's ever made was exercising 58,332 units of Zomedica Pharmaceuticals stock on 12 April 2021 worth over $9,333. On average, Ann trades about 19,444 units every 5 days since 2020. As of 3 May 2021 she still owns at least 8,333 units of Zomedica Pharmaceuticals stock.

You can see the complete history of Ms. Cotter stock trades at the bottom of the page.

Ann Cotter biography

Ann Cotter CPA serves as Chief Financial Officer, Secretary of the Company. Ms. Cotter has been the Company’s Interim Chief Financial Officer and Corporate Secretary since August 2020. From August 2018 to August 2020, she served as the Company’s Vice President, Finance. From April 2018 until August 2018, Ms. Cotter served as the chief financial officer of American Fence & Supply Co., Inc. From January 2018 until March 2018, she was a consultant to Aston Carter, a professional placement services company. From August 2014 until September 2017, she served as the corporate controller to Promotion Technology Group, an audio visual solutions company. Ms. Cotter holds a Master of Taxation from Capital University Law School and a Bachelor of Arts in Economics and Spanish from Capital University. She is a Certified Public Accountant, licensed in Ohio since 1996.

How old is Ann Cotter?

Ann Cotter is 50, she's been the Chief Financial Officer and Secretary of Zomedica Pharmaceuticals since 2020. There are 7 older and 4 younger executives at Zomedica Pharmaceuticals. The oldest executive at Zomedica Pharmaceuticals Corp. is Robert W. DiMarzo, 64, who is the Consultant.

What's Ann Cotter's mailing address?

Ann's mailing address filed with the SEC is C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR, MI, 48018.

Insiders trading at Zomedica Pharmaceuticals

Over the last 5 years, insiders at Zomedica Pharmaceuticals have traded over $7,040 worth of Zomedica Pharmaceuticals stock and bought 3,375,000 units worth $601,250 . The most active insiders traders include Robert Cohen, Johnny D Powers, and Stephanie Morley. On average, Zomedica Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $39,452. The most recent stock trade was executed by Larry C Ii Heaton on 5 September 2024, trading 100,000 units of ZOM stock currently worth $13,000.

What does Zomedica Pharmaceuticals do?

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Complete history of Ms. Cotter stock trades at Zomedica Pharmaceuticals

Zomedica Pharmaceuticals executives and stock owners

Zomedica Pharmaceuticals executives and other stock owners filed with the SEC include:

• Dr. Stephanie Laine Morley D.V.M., DVM,
  Consultant
• Bruk Herbst,
  Chief Commercial Officer
• Ann Marie Cotter CPA,
  CFO & Sec.
• Rodney Williams,
  Independent Member
• Thomas Robitaille,
  Independent Director
• Johnny Powers,
  Independent Director
• Christopher MacLeod,
  Independent Director
• Jane Eagleson,
  Independent Director
• Christopher Wolfenberg,
  Director
• Angie Moricz,
  Executive Administrative Assistant
• Bruk Herbst,
  Chief Commercial Officer
• Angy Guerrant,
  Director of Portfolio Management
• Andrea Eberle,
  Senior Marketing Manager
• William MacArthur,
  Executive Member and Chief Medical Officer, Director of Research and Development
• Ann Cotter,
  Chief Financial Officer, Secretary
• Robert Cohen,
  Interim Chief Executive Officer, Director
• Stephanie Morley,
  President, Chief Operating Officer
• Jeffrey Rowe,
  Chairman of the Board
• Kristin Domanski,
  VP of HR
• Nicole Westfall,
  VP of Marketing
• Tony Blair,
  Exec. VP of Operations
• Larry C. Heaton II,
  Pres & CEO
• Robert W. DiMarzo,
  Consultant
• Dr. William Carpenter MacArthur,
  Consultant
• David Eaton,
  VP of Marketing
• Michael Schilk,
  VP of Sales
• Sean Whelan,
  
• Russell Kevin Klass,
  Vice President of Sales
• Rampertab Shameze,
  
• James Le Bar,
  Director
• Adrian Lock,
  VP and General Manager
• Larry C Ii Heaton,
  CEO
• Pamela Nichols,
  
• Anthony K Blair,
  COO
• Peter Donato,
  Chief Financial Officer